Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

DAPtomycin

DAPtomycin
  • Restricted Miscellaneous Program Formulary
  • Restricted Cubicin --> Restricted to Infectious Diseases providers ~OR~ any prescriber for acute skin and skin structure infections.
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Cubicin POWDER FOR INJECTION, INTRAVENOUS 250 mg, 500 mg      
VIEW MORE Cyclic Lipopeptides
CLASS
08122812
Comments:

 DAPtomycin is classified as formulary, restricted; use for skin and skin structure infections is approved for all prescribers (6 mg/kg once daily dose recommended). Treatment of all other infectious diseases is restricted to ID. 

Dose Rounding: Nearest 50 mg increment for patients 18 years and over. Use total body weight in non-obese patients and adjusted body weight in obese patients (obese if TBW/IBW is ≥130% or BMI ≥30).

Recommended AdjBW equation for daptomycin: AdjBW = IBW + 0.4(TBW-IBW)

Automatic renal adjustment per guidelines. See Antimicrobial Dosing Guideline and Renal Adjustment Policy (Adult) for more information.  CrCl calculation policy available here.

Weekly CPK monitoring.

Reviewed: 26 May 2015 (Cubicin), June 2020 (Administration Time), May 2025

Daptomycin SBAR Update May 2025.pdf

Last updated: Jun. 12, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved